Literature DB >> 17171028

Prognostic Factors Including Proliferation Markers Ki-67, bax, and bcl-2 in Temporal Bone Paraganglioma.

M Gjuric, U Völker, A Katalinic, S R Wolf.   

Abstract

Valuable criteria with which to predict the clinical behavior of the temporal bone paraganglioma or the response to treatment are lacking. The analysis of markers of cell proliferation is a possibility to estimate the prognosis. Extensive patient data on 40 temporal bone paragangliomas were gathered over the years and correlated with the data obtained by staining histologic sections with bcl-2, bax, and MIB I markers of cellular proliferation. The immunohistochemistry was in all cases negative for bcl-2, positive for bax, and for Ki-67 positive in 20% of tumors. The scores for Ki-67 did not correlate with the majority of clinical parameters, except for treatment modality, preoperative hearing loss, and cranial nerve involvement. The tendency toward poorer hearing and a higher incidence of preoperative lower cranial nerve palsies was demonstrated in patients with higher Ki-67 scores. Furthermore, the higher rate of subtotal tumor removals in these patients reveals technical difficulties in accomplishing a radical removal, although the incidence of residual tumors was thus not affected. In view of the present information obtained with proliferation markers, the site of tumor origin still remains the most predictive variable for the course of the disease.

Entities:  

Year:  1997        PMID: 17171028      PMCID: PMC1656651          DOI: 10.1055/s-2008-1058593

Source DB:  PubMed          Journal:  Skull Base Surg        ISSN: 1052-1453


  33 in total

1.  Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections.

Authors:  G Cattoretti; S Pileri; C Parravicini; M H Becker; S Poggi; C Bifulco; G Key; L D'Amato; E Sabattini; E Feudale
Journal:  J Pathol       Date:  1993-10       Impact factor: 7.996

2.  Immunohistochemistry of glomus jugulare and tympanicum tumors.

Authors:  S Branica; N Sprem; Z Danilović; S Seiwerth
Journal:  Acta Med Croatica       Date:  1993

3.  Glomus jugulare tumors. Methods and difficulties of diagnosis and surgical treatment.

Authors:  J S Brown
Journal:  Laryngoscope       Date:  1967-01       Impact factor: 3.325

4.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.

Authors:  S Krajewski; M Krajewska; A Shabaik; T Miyashita; H G Wang; J C Reed
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

Review 7.  Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas.

Authors:  C Capella; C Riva; M Cornaggia; A M Chiaravalli; B Frigerio; E Solcia
Journal:  Pathol Res Pract       Date:  1988-04       Impact factor: 3.250

8.  Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.

Authors:  E Karamitopoulou; E Perentes; I Diamantis; T Maraziotis
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

9.  Prognostic significance of Ki-67 reactivity in soft tissue sarcomas.

Authors:  T Ueda; K Aozasa; M Tsujimoto; M Ohsawa; A Uchida; Y Aoki; K Ono; K Matsumoto
Journal:  Cancer       Date:  1989-04-15       Impact factor: 6.860

10.  Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.

Authors:  S Krajewski; C Blomqvist; K Franssila; M Krajewska; V M Wasenius; E Niskanen; S Nordling; J C Reed
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.